• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial
Conclusion The majority of deaths occurred in patients who did not experience a non-fatal CV or renal event, although the risk of death was higher following an event. Our findings illustrate continuing opportunities to reduce morbidity and mortality in patients with type 2 diabetes.
Source: European Heart Journal - September 21, 2015 Category: Cardiology Authors: Jhund, P. S., McMurray, J. J. V., Chaturvedi, N., Brunel, P., Desai, A. S., Finn, P. V., Haffner, S. M., Solomon, S. D., Weinrauch, L. A., Claggett, B. L., Pfeffer, M. A. Tags: Prevention and epidemiology Source Type: research

Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial
Conclusions Sizeable reductions in BP, with potential for substantial CVD reduction, can be safely achieved using combinations of BP drugs in the elderly with normal high and Stage 1 hypertension. Clinical trial registration NCT01259297.
Source: European Heart Journal - July 7, 2014 Category: Cardiology Authors: Teo, K. K., Pfeffer, M., Mancia, G., O'Donnell, M., Dagenais, G., Diaz, R., Dans, A., Liu, L., Bosch, J., Joseph, P., Copland, I., Jung, H., Pogue, J., Yusuf, S., on behalf of the Aliskiren Prevention of Later Life Outcomes trial Investigators Tags: Hypertension Source Type: research